Does UBS’s Focus on Great-West Lifeco’s Inorganic Growth Shift Its Investment Narrative? (TSX:GWO)

• Earlier this week, UBS initiated coverage on Great-West Lifeco Inc, assigning a Buy rating and emphasizing the insurer’s significant resources, with over C$2 billion in holding company cash and more than C$10 billion in liquidity available for growth and acquisitions.
• The UBS report also pointed out Great-West’s increased focus on inorganic expansion and a rising contribution from US operations, now approaching half of earnings, as central themes for its growth profile.
• We'll explore how UBS’s positive outlook on Great-West’s acquisition strategy could refresh the company’s medium-term investment narrative.

We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Great-West Lifeco Investment Narrative Recap

To be a shareholder in Great-West Lifeco, you need to believe in its ability to leverage substantial financial resources and execute disciplined acquisitions, particularly in the U.S. market, all while managing competitive pressures and fee compression in its core retirement and wealth management segments. UBS’s recent Buy rating highlights the company’s deep liquidity and potential for inorganic growth, but this news alone does not materially impact the biggest near-term catalyst: ongoing U.S. expansion, nor does it meaningfully offset the risk of revenue pressure from shifting demographics and outflows in the U.S. Retirement business.

Among recent announcements, Great-West Lifeco’s increased share buyback authority stands out as highly relevant to the current growth narrative. The combination of robust capital allocation and active repurchases could support earnings per share and provide flexibility in pursuing select transactions, reinforcing the short-term focus on balancing capital returns with U.S. growth amid ongoing market volatility.

Yet, in contrast to the company’s strong position for U.S. growth, investors should also be aware of the ongoing risks posed by persistently elevated participant outflows in retirement businesses, as ...

Read the full narrative on Great-West Lifeco (it's free!)

Great-West Lifeco's narrative projects CA$41.6 billion in revenue and CA$4.3 billion in earnings by 2028. This requires 5.8% yearly revenue growth and a CA$0.6 billion earnings increase from the current CA$3.7 billion.

Uncover how Great-West Lifeco's forecasts yield a CA$56.50 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Simply Wall St Community members assigned Great-West Lifeco fair values ranging between C$56.50 and C$131.26, based on three individual perspectives. While many see upside, ongoing competition and fee compression in workplace retirement remain a factor that could weigh on future returns. Explore the full spectrum of community valuations and opinions before making up your mind.

Explore 3 other fair value estimates on Great-West Lifeco - why the stock might be worth just CA$56.50!

Build Your Own Great-West Lifeco Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Great-West Lifeco research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Great-West Lifeco research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Great-West Lifeco's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 37 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com